Across TCGA pan-cancer cohorts, CARD16 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of CARD16’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CARD16 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CARD16 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where CARD16 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CARD16 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	+1.163	<.001	12	view →
LUAD	Female	II,III,IV	−0.717	<.001	9	view →
LSCC	Male	III,IV	−0.924	<.001	8	view →
HNSC	Male	All	+0.595	<.001	8	view →
OV	All	All	+0.432	.031	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: CARD16 RNA expression & survival · all CARD16 data types